Literature DB >> 23159233

Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study.

Mohit A Limdi, Michael R Crowley, T Mark Beasley, Nita A Limdi, Michael Allon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23159233      PMCID： PMC3654383          DOI： 10.1053/j.ajkd.2012.09.012

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  7 in total

1.  When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.

Authors:  S-M Huang; R Temple; S Xiao; L Zhang; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2009-11       Impact factor: 6.875

2.  The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report.

Authors:  Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt
Journal:  Kidney Int       Date:  2010-12-08       Impact factor: 10.612

3.  Prevalence of chronic kidney disease in the United States.

Authors:  Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey
Journal:  JAMA       Date:  2007-11-07       Impact factor: 56.272

4.  Kidney function influences warfarin responsiveness and hemorrhagic complications.

Authors:  Nita A Limdi; T Mark Beasley; Melissa F Baird; Joyce A Goldstein; Gerald McGwin; Donna K Arnett; Ronald T Acton; Michael Allon
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

5.  Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors:  N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal:  Clin Pharmacol Ther       Date:  2007-07-25       Impact factor: 6.875

6.  Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin Optimized Outpatient Follow-up Study Group.

Authors:  S D Fihn; M McDonell; D Martin; J Henikoff; D Vermes; D Kent; R H White
Journal:  Ann Intern Med       Date:  1993-04-01       Impact factor: 25.391

7.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391
  7 in total
  7 in total

1.  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

Authors:  Nita A Limdi; Thomas D Nolin; Sarah L Booth; Amanda Centi; Marisa B Marques; Michael R Crowley; Michael Allon; T Mark Beasley
Journal:  Am J Kidney Dis       Date:  2014-11-25       Impact factor: 8.860

2.  Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Authors:  Aditi Shendre; Gaurav M Parmar; Chrisly Dillon; Timothy Mark Beasley; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2018-02-27       Impact factor: 4.705

3.  The Kidney Disease Screening and Awareness Program (KDSAP): a novel translatable model for increasing interest in nephrology careers.

Authors:  Li-Li Hsiao; Jingshing Wu; Albert C Yeh; Eric C Shieh; Cheryl Cui; Ang Li; Laura C Polding; Rayhnuma Ahmed; Kenneth Lim; Tzong-Shi Lu; Connie M Rhee; Joseph V Bonventre
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

4.  Lower CYP2C9 activity in Turkish patients with Behçet's disease compared to healthy subjects: a down-regulation due to inflammation?

Authors:  Mustafa Tugrul Goktaş; Fazleen Hatta; Ozgur Karaca; Said Kalkisim; Levent Kilic; Ali Akdogan; Melih O Babaoglu; Atilla Bozkurt; Anders Helldén; Leif Bertilsson; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2015-08-02       Impact factor: 2.953

5.  Risk Factors for Major Hemorrhage Among Patients Receiving Dabigatran Across the Spectrum of CKD Not Requiring Dialysis Therapy.

Authors:  Brittney H Davis; Rajbeer Sangha; Chrisly Dillon; Todd M Brown; Renuka Narayan; Mark Beasley; Tom McElderry; Thomas D Nolin; Nita A Limdi
Journal:  Am J Kidney Dis       Date:  2020-12-02       Impact factor: 11.072

6.  Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.

Authors:  Nita A Limdi; Timothy Mark Beasley; Jielin Sun; Norman Stockbridge; Michael Pacanowski; Jeffry Florian
Journal:  Clin Pharmacol Ther       Date:  2021-01-19       Impact factor: 6.903

7.  Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.

Authors:  Karolina Szummer; Alessandro Gasparini; Staffan Eliasson; Johan Ärnlöv; Abdul Rashid Qureshi; Peter Bárány; Marie Evans; Leif Friberg; Juan Jesus Carrero
Journal:  J Am Heart Assoc       Date:  2017-03-01       Impact factor: 5.501
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.